Madrigal Pharmaceuticals Inc (MDGL NASDAQ) stock market data APIs
$418.606
10.62(2.5%)
as of September 17, 2025
Try our APIs with
free plan!
Madrigal Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
Prev. Close
418.606
Open
429.2287
High
432.2224
Low
413.8807
52 wk Range
200.63-457.16
Market Cap
9 519 M
Shares Outstanding
22 289 K
Revenue
516 M
EPS
-1.9
Beta
-1.025
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Madrigal Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Madrigal Pharmaceuticals Inc data using free add-ons & libraries
Get Madrigal Pharmaceuticals Inc Fundamental Data
Madrigal Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 516 M
- EBITDA: -308 396 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-05
- EPS/Forecast: -3.63
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Madrigal Pharmaceuticals Inc News
New
A Fresh Look at Madrigal Pharmaceuticals (MDGL) Valuation Following Recent Share Price Momentum
Madrigal Pharmaceuticals (MDGL) has been catching eyes lately as its share price continues to move higher. This has raised questions among investors about what is driving the momentum behind this biot...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-ass...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics...
TD Cowen Sees Greater Upside in Madrigal (MDGL) Following Recent Rezdiffra Approval
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the most shorted stocks right now. On August 25, TD Cowen analyst Ritu Baral raised her price target on Madrigal Pharmaceuticals (NASDAQ:MDGL) to ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
